AR127317A1 - Rna terapéutico para el cáncer de pulmón - Google Patents
Rna terapéutico para el cáncer de pulmónInfo
- Publication number
- AR127317A1 AR127317A1 ARP220102747A ARP220102747A AR127317A1 AR 127317 A1 AR127317 A1 AR 127317A1 AR P220102747 A ARP220102747 A AR P220102747A AR P220102747 A ARP220102747 A AR P220102747A AR 127317 A1 AR127317 A1 AR 127317A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunogenic
- amino acid
- acid sequence
- variant
- mage
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title 1
- 201000005202 lung cancer Diseases 0.000 title 1
- 208000020816 lung neoplasm Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 18
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 10
- 239000012634 fragment Substances 0.000 abstract 6
- 201000001441 melanoma Diseases 0.000 abstract 4
- 102000003859 Claudin-6 Human genes 0.000 abstract 3
- 108090000229 Claudin-6 Proteins 0.000 abstract 3
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 abstract 3
- 101710203618 Kita-kyushu lung cancer antigen 1 Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000001900 immune effect Effects 0.000 abstract 2
- 239000002479 lipoplex Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 101710135378 pH 6 antigen Proteins 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/078022 WO2023061550A1 (en) | 2021-10-11 | 2021-10-11 | Therapeutic rna for lung cancer |
| EP2022050135 | 2022-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127317A1 true AR127317A1 (es) | 2024-01-10 |
Family
ID=84286153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102747A AR127317A1 (es) | 2021-10-11 | 2022-10-11 | Rna terapéutico para el cáncer de pulmón |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240415946A1 (https=) |
| EP (1) | EP4415747A1 (https=) |
| JP (1) | JP2024537298A (https=) |
| KR (1) | KR20240099175A (https=) |
| AR (1) | AR127317A1 (https=) |
| AU (1) | AU2022365280A1 (https=) |
| CA (1) | CA3234915A1 (https=) |
| IL (1) | IL312026A (https=) |
| MX (1) | MX2024004421A (https=) |
| TW (1) | TW202333803A (https=) |
| WO (1) | WO2023061931A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025201659A1 (en) * | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001231204A1 (en) * | 2000-01-27 | 2001-08-07 | Sidney Kimmel Cancer Center | Genetically engineered tumor cell vaccines |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| US20180126003A1 (en) * | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| TW202134430A (zh) * | 2019-12-03 | 2021-09-16 | 美商紐沃進公司 | 腫瘤細胞疫苗 |
-
2022
- 2022-10-07 TW TW111138246A patent/TW202333803A/zh unknown
- 2022-10-10 EP EP22802066.5A patent/EP4415747A1/en active Pending
- 2022-10-10 CA CA3234915A patent/CA3234915A1/en active Pending
- 2022-10-10 IL IL312026A patent/IL312026A/en unknown
- 2022-10-10 WO PCT/EP2022/078084 patent/WO2023061931A1/en not_active Ceased
- 2022-10-10 MX MX2024004421A patent/MX2024004421A/es unknown
- 2022-10-10 AU AU2022365280A patent/AU2022365280A1/en active Pending
- 2022-10-10 US US18/699,937 patent/US20240415946A1/en active Pending
- 2022-10-10 JP JP2024521854A patent/JP2024537298A/ja active Pending
- 2022-10-10 KR KR1020247012038A patent/KR20240099175A/ko active Pending
- 2022-10-11 AR ARP220102747A patent/AR127317A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024004421A (es) | 2024-05-06 |
| WO2023061931A1 (en) | 2023-04-20 |
| IL312026A (en) | 2024-06-01 |
| US20240415946A1 (en) | 2024-12-19 |
| JP2024537298A (ja) | 2024-10-10 |
| TW202333803A (zh) | 2023-09-01 |
| EP4415747A1 (en) | 2024-08-21 |
| AU2022365280A1 (en) | 2024-05-02 |
| KR20240099175A (ko) | 2024-06-28 |
| CA3234915A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021016301A2 (es) | Arn terapéutico para cáncer de ovario | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| MX2020003995A (es) | Nuevas moleculas de acido nucleico artificiales. | |
| CO2020014727A2 (es) | Anticuerpo anti proteína reguladora de señales alfa sirpαlfa | |
| CO2017007293A2 (es) | Dinucleótidos cíclicos útiles para el tratamiento de (inter alia) cáncer | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| CO2021011892A2 (es) | Arn terapéutico para el cáncer de próstata | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| PE20210628A1 (es) | Anticuerpos anti-cd73 y metodos de uso de los mismos | |
| MX2025004075A (es) | Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos | |
| MX2024002725A (es) | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos que comprenden fosfatidilserina. | |
| MX2016002154A (es) | Vacuna contra el virus respiratorio sincitial. | |
| CO2026004333A2 (es) | Inhibidores de ras-pi3k para el tratamiento del cáncer y enfermedades inmunológicas | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| CR20250273A (es) | Compuesto quimérico protac, método de preparación del mismo y uso del mismo | |
| AR127317A1 (es) | Rna terapéutico para el cáncer de pulmón | |
| PE20180741A1 (es) | Anticuerpo anti-cd154 con caracteristicas de union, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana | |
| AR101871A1 (es) | Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos | |
| CL2019003409A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| MX2021004907A (es) | Vacuna de ibv 4/91 con proteina espicular heterologa. | |
| PE20221326A1 (es) | Anticuerpos anti-mertk y metodos de uso de los mismos | |
| AR127324A1 (es) | Rna terapéutico para el cáncer de pulmón | |
| CO2020013699A2 (es) | Composiciones aav, métodos de fabricación y métodos de uso | |
| UY39464A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| AR116878A1 (es) | Vacuna de ibv h52 con proteína espicular heteróloga |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |